The hēRo3 Revolution: Accelerating and Empowering HEOR Analytics with Cutting-Edge Digital Solutions

With the rapid pace of breakthroughs in biopharma, the marketplace is becoming increasingly competitive. As a result, companies need to ensure that early pipeline asset planning is focused on “value-for-money” strategies.

HEOR teams can now meaningfully contribute at the decision-making table by providing rapid turnaround of HEOR models and presenting critical insights that are intuitive and engaging in real-time.  

In this interview, first published in HealthEconomics.com, Chad Rose, General Manager hēRo3, explains how. 

 

Why is there a need to revolutionize the way HEOR insights are used in the decision-making process? 

Now more than ever, there is a heightened importance for companies to ensure that bets made on new pipeline assets are both thoughtful and strategic. With the rapid pace of breakthroughs in biopharma, the marketplace is becoming increasingly competitive. This results in companies targeting smaller patient populations while continuing to incur significant fixed costs, placing greater focus on “value-for-money insights for new interventions. Companies that plan on gaining or maintaining a competitive advantage need tools to make fast and informed decisions for clinical development assets. 

Due to the industry’s reliance on using Excel for their modeling needs, some HEOR teams can’t perform the analytics fast enough to contribute at the decision-making table when they are called upon. Excel simply isn’t equipped to keep up with the innovation needs that companies now demand or can be achieved through recent advances in alternative technologies. 

 

The hēRo3 platform solves this need by revolutionizing the way HEOR insights can and should be used in the decision-making process. 

Learn more about hēRo3 at: www.heroapps.io 

 

What is hēRo3? 

hēRo3 (health economics in R online) is a secure cloud platform for building, running, and sharing Markov cohort and partitioned survival models. Computations are performed using a heavily tested, open-source R modeling package, and all models and data are encrypted in transit and at rest. 

hēRo3 simplifies model builds with an easy and streamlined setup of many critical analyses including: 

  • Deterministic and probabilistic sensitivity analyses 
  • Threshold analyses 
  • 2-way sensitivity analyses 
  • Scenario analyses 
  • Value-based pricing calculator 

All models are equipped with automated, interactive, and presentation-ready displays including: 

  • Tornado diagrams 
  • Trace diagrams 
  • Waterfall charts 
  • Efficiency frontiers 
  • Bar charts
  • Heat maps 
  • Scatter plots 
  • Tabular 
  • State transition diagrams 

 

Learn more about hēRo3 at: www.heroapps.io 


Why are companies using hēRo3?
 

  • hēRo3 provides rapid, on-demand insights to clinical and commercial teams

  • Animated and interactive visualizations answer critical HEOR questions in realtime, providing easily digestible outputs to both technical and nontechnical audiences

  • Shorter workflows allow clients to incorporate critical HEOR insights early and often, ensuring they are making the most informed decisions possible for their clinical development assets

  • hēRo3’s structured approach to building models helps facilitate a seamless transfer of knowledge when staffing changes and organizational restructuring occurs, allowing our experts or other team members to easily pick up where others dropped off and maintain project timelines

  • Improves HEOR workflows and supports team collaboration through a wellorganized model Workspace and clear permissions controls 

Learn more about hēRo3 at: www.heroapps.io 


How are companies using hēRo3?
 

Here are a few examples of how hēRo3 is being used across the industry:

Strategy 

  • Optimizing trial designs by improving patient selection criteria, trial endpoints, and outcomes, or refining the included interventions and comparators 
  • Informing business development initiatives such as M&A and licensing decisions using robust information on economically justifiable prices, anticipated cost-effectiveness stories, and potential hurdles that assets may face before going to market 

  

HEOR and Market Access Planning 

  • Estimating economically justifiable prices for early pipeline assets 
  • Developing economic value propositions and optimizing value stories through testing and refinement 
  • Identifying inputs that are key value drivers of cost-effectiveness 
  • Efficiently allocating resources towards new HEOR evidence generation based on anticipated impact that new evidence may yield with respect to cost-effectiveness and value-for-money 
  • Replicating ICER models and incorporating early assets into economic comparisons 

  

HTA Model Support 

  • Validating Excel models by building replications in hēRo3 
  • Building multiple protype models to test alternative model frameworks to identify an optimal model structure  

Which companies are already benefitting from hēRo3? 

It ranges from the biggest names in biopharmaceuticals that use hēRo3 across their entire portfolio of early pipeline assets; to partnering with emerging biopharma companies to build out HEOR capabilities while allowing them to harness critical insights provided by our experts.

We offer flexible service solutions to meet a wide variety of client needs. Your organization can partner with our experts to receive presentation-ready models, or we can train your internal teams to build their own models. 

Either way, hēRo3 allows you to realize the benefit of incorporating critical HEOR insights into workflows early and often.  

Learn more about hēRo3 at: www.heroapps.io 

FREE Ebook

Precision medicine

Latest insights

Driving BioPharma Access in Europe: Insights for ...

PRMA Consulting becomes Avalere Health, creating the ...

World Orphan Drug Congress 2023: solutions for market ...

Webinars

Driving BioPharma Access in Europe: Insights ...

Read more >

EBOOK

Value, Evidence, and Access: insights for ...

Read more >

EBOOK

Digital therapeutics: policy, access, value, and ...

Read more >

Blog

Evidence generation and launch strategies in ...

Read more >

Articles

Value, Evidence, and Access: insights for ...

Read more >

Blog

Digital therapeutics: value, evidence, and access ...

Read more >

EBOOK

Precision medicine: positioning for market access ...

Read more >

Blog

Welcoming Philip Drew, Head of Global ...

Read more >

Blog

Evidence supporting reimbursement of digital therapeutics

Read more >

Blog

Reducing the care gap in cancer ...

Read more >

Blog

ISPOR 2023: insight from Avalere’s expert ...

Read more >

Webinars

Positioning for market access success in ...

Read more >

Blog

AMCP 2023: key trends and highlights

Read more >

Blog

Why a market access career in ...

Read more >

Blog

E-learning for market access professionals

Read more >

Blog

Showcasing Robust Policy, Access, Value, and ...

Read more >

Blog

Principles of HTA Early Scientific Advice ...

Read more >

Blog

Driving BioPharma value, evidence, and access ...

Read more >

Articles

Market access success in the evolving ...

Read more >

Blog

5 benefits of e-learning for your market ...

Read more >

Articles

Cell and gene therapy: navigating the ...

Read more >

Blog

Market access careers in the Asia-Pacific ...

Read more >

Blog

Driving BioPharma value, evidence, and access ...

Read more >

Blog

The benefits of utilizing Early Scientific ...

Read more >

Blog

Driving BioPharma value, evidence, and access ...

Read more >

Blog

Cell and gene therapies: common challenges ...

Read more >

Blog

Avalere’s Healthcare Industry Outlook Report 2023

Read more >

Blog

Driving BioPharma value, evidence, and access ...

Read more >